| 000 | 01640cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030715.0 | ||
| 008 | 121118s2012 ua db f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.12.04.Ph.D.2012.No.E | ||
| 100 | 0 | _aNoha Ali Mohammed Saleh | |
| 245 | 1 | 0 |
_aEvaluation of anti hepatitis C virus compounds / _cNoha Ali Mohammed Saleh ; Supervised Anwar Abdelazim Elsayed , Wael M. Elshemey , Medhat Ibrahim |
| 246 | 1 | 5 | _aتقييم مركبات مضادة للفيروس الكبدي سي |
| 260 |
_aCairo : _bNoha Ali Mohammed Saleh , _c2012 |
||
| 300 |
_a149 P. : _bcharts , maps ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Science - Department of Biophysics | ||
| 520 | _aHepatitis C virus (HCV) represents a major challenge for the health community in Egypt. It is the most widely spread viral infection of liver. Knowing that the currently available treatment (interferon-Ü and ribavirin combination) is expensive and effective only on 50-60% of treated patients, it is thus crucially important to exert maximum effort in the design of new formulations aiming to achieve better treatment performance | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aCellulose | |
| 653 | 4 | _aHCV | |
| 653 | 4 | _aNS3 protease | |
| 700 | 0 |
_aAnwar Abdelazim Elsayed , _eSupervisor |
|
| 700 | 0 |
_aMedhat Ibrahim , _eSupervisor |
|
| 700 | 0 |
_aWael M. Elshemey , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c40243 _d40243 |
||